journal article·2016-09

Tumor‐Microenvironment‐Adaptive Nanoparticles Codeliver Paclitaxel and siRNA to Inhibit Growth and Lung Metastasis of Breast Cancer

Shan Tang, Qingshuo Meng, Huiping Sun, Jinghan Su, Qi Yin, Zhiwen Zhang, Haijun Yu, Lingli Chen, Yi Chen, Wangwen Gu, Yaping Li

Advanced Functional Materials· Volume 26· Issue 33
Publisher page

Abstract

Prolonged circulation, specific and effective uptake by tumor cells, and rapid intracellular drug release are three main factors for the drug delivery systems to win the battle against metastatic breast cancer. In this work, a tumor microenvironment‐adaptive nanoparticle co‐loading paclitaxel (PTX) and the anti‐metastasis siRNA targeting Twist is prepared. The nanoparticle consists of a pH‐sensitive core, a cationic shell, and a matrix metalloproteinase (MMP)‐cleavable polyethylene glycol (PEG) corona conjugated via a peptide linker. PEG will be cut away by MMPs at the tumor site, which endows the nanoparticle with smaller particle size and higher positive charge, leading to more efficient cellular uptake in tumor cells and higher intra‐tumor accumulation of both PTX and siRNA in the 4T1 tumor‐bearing mice models compared to the nanoparticles with irremovable PEG. In addition, acid‐triggered drug release in endo/lysosomes is achieved through the pH‐sensitive core. As a result, the MMP/pH dual‐sensitive nanoparticles significantly inhibit tumor growth and pulmonary metastasis. Therefore, this tumor‐microenvironment‐adaptive nanoparticle can be a promising codelivery vector for effective therapy of metastatic breast cancer due to simultaneously satisfying the requirements of long circulating time, efficient tumor cell targeting, and fast intracellular drug release.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Drug Research & Center of Pharmaceutics Shanghai Institute of Materia Medica Chinese Academy of Sciences 501 Haike Road Shanghai 201203 China

School of Pharmacy Shenyang Pharmaceutical University Shenyang 110016 China

School of Pharmacy Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong Yantai University Yantai 264005 China

Funding

National Natural Science Foundation of China · Youth Innovation Promotion Association of the Chinese Academy of Sciences

References (42)

Show source-provided references
1. 10.1038/nature1141210.1038/nature11412 ↗
2. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
3. 10.1158/0008-5472.CAN-11-062710.1158/0008-5472.CAN-11-0627 ↗
4. 10.1002/adfm.20110219110.1002/adfm.201102191 ↗
5. 10.1021/nn300524f10.1021/nn300524f ↗
6. 10.1038/nrd261410.1038/nrd2614 ↗
7. 10.1038/nrd259110.1038/nrd2591 ↗
8. 10.1002/adfm.20140233810.1002/adfm.201402338 ↗
9. 10.1016/j.jconrel.2014.10.02410.1016/j.jconrel.2014.10.024 ↗
10. 10.1002/smll.20090115810.1002/smll.200901158 ↗
11. 10.1016/j.biotechadv.2013.11.00910.1016/j.biotechadv.2013.11.009 ↗
12. 10.1038/nmat377610.1038/nmat3776 ↗
13. 10.1021/nn204240b10.1021/nn204240b ↗
14. 10.1016/j.jconrel.2015.04.03810.1016/j.jconrel.2015.04.038 ↗
15. 10.1016/j.cell.2010.03.01510.1016/j.cell.2010.03.015 ↗
16. 10.1016/j.biomaterials.2014.05.05010.1016/j.biomaterials.2014.05.050 ↗
17. 10.1016/j.biomaterials.2015.01.04910.1016/j.biomaterials.2015.01.049 ↗
18. 10.1007/s13277-013-1002-x10.1007/s13277-013-1002-x ↗
19. 10.1016/j.jconrel.2015.03.01110.1016/j.jconrel.2015.03.011 ↗
20. 10.1016/0167-4838(95)00259-610.1016/0167-4838(95)00259-6 ↗
21. 10.1016/j.biomaterials.2014.04.02510.1016/j.biomaterials.2014.04.025 ↗
22. 10.1002/adfm.20120114010.1002/adfm.201201140 ↗
23. 10.1002/adfm.20150154810.1002/adfm.201501548 ↗
24. 10.1021/nn500299p10.1021/nn500299p ↗
25. 10.1021/ja408879b10.1021/ja408879b ↗
26. 10.1021/mp400337f10.1021/mp400337f ↗
27. 10.1007/s11434-014-0719-210.1007/s11434-014-0719-2 ↗
28. 10.1002/adma.20150428810.1002/adma.201504288 ↗
29. 10.1016/j.ymthe.2005.02.01010.1016/j.ymthe.2005.02.010 ↗
30. 10.1021/nn303955n10.1021/nn303955n ↗
31. 10.1016/j.etap.2012.03.00410.1016/j.etap.2012.03.004 ↗
32. 10.1002/adfm.20150072410.1002/adfm.201500724 ↗
33. 10.1016/j.ijpharm.2005.10.01010.1016/j.ijpharm.2005.10.010 ↗
34. 10.1007/s11095-012-0874-610.1007/s11095-012-0874-6 ↗
35. 10.2217/nnm.11.14110.2217/nnm.11.141 ↗
36. 10.1016/j.jconrel.2015.08.01210.1016/j.jconrel.2015.08.012 ↗
37. 10.1016/j.cell.2004.07.01110.1016/j.cell.2004.07.011 ↗
38. 10.1158/0008-5472.CAN-11-133810.1158/0008-5472.CAN-11-1338 ↗
39. 10.1038/onc.2014.12310.1038/onc.2014.123 ↗
40. 10.1093/carcin/bgt28210.1093/carcin/bgt282 ↗
41. Merdad A. · Anticancer Res. · 2014 · 34 · 1355
42. 10.3892/ijo.2013.203110.3892/ijo.2013.2031 ↗